On Friday, 1 March at 14:00 CET, the company's executive management will host a conference call and webcast discussion of the results and provide an update on the pipeline programs and partnering activities. Access to the event can be obtained as follows:

LIVE access on Friday 1 March at 14:00 CET

Telephone numbers:

SE: +46 85 664 2705

DK: +45 7815 0110

UK: +44 33 3300 9034

US: +1 833 5268 380

Webcast will be available at www.nuevolution.com in the Investors section and at www.financialhearings.com 

REPLAY access

Webcast replay will be available at www.nuevolution.com in the Investors section and at www.financialhearings.com 

For more information, please contact:

Alex Haahr Gouliaev, CEO

Phone: +45 3913 0902

Email: ahg@nuevolution.com

Johnny Stilou, CFO

Phone: +45 8877 5973

Email: jost@nuevolution.com

Information about Nuevolution AB (publ)

Nuevolution AB (publ) is a leading small molecule drug discovery biotech company founded in 2001, and headquartered in Copenhagen, Denmark. Nuevolution partners its discovery platform and programs with pharmaceutical and biotechnology companies to seek future benefit of patients in need of novel medical treatment option. Nuevolution's internal programs are focused on therapeutically important targets within inflammation, oncology and immuno-oncology.

The information was sent for publication, through the agency of the contact persons set out above, on Thursday 21 February 2019, 18:00 CET.

Nuevolution AB (publ) is listed at Nasdaq in Stockholm, Sweden (ticker: NUE). More information about Nuevolution can be found on: www.nuevolution.com